Introduction

Oncology Reports

1021-335X 1791-2431

D.A. Spandidos

10.3892/or.2019.7351

OR-0-0-7351

Review

Role of anabolic agents in colorectal carcinogenesis: Myths and realities

Krasanakis

Theodore

1 * Nikolouzakis

Taxiarchis Konstantinos

1 * Sgantzos

Markos

2 Mariolis-Sapsakos

Theodore

3 Souglakos

John

4 Spandidos

Demetrios A.

5 Tsitsimpikou

Christina

6 Tsatsakis

Aristidis

7 Tsiaoussis

John

1Laboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, 71110 Heraklion, Greece 2Faculty of Medicine, Department of Anatomy, Faculty of Medicine, University of Thessaly, 41221 Larissa, Greece 3National and Kapodistrian University of Athens, Agioi Anargyroi General and Oncologic Hospital of Kifisia, 14564 Athens, Greece 4Department of Medical Oncology, University General Hospital of Heraklion, 71110 Heraklion, Greece 5Laboratory of Clinical Virology, Medical School, University of Crete, 71409 Heraklion, Greece 6General Chemical State Laboratory of Greece, 11521 Athens, Greece 7Department of Forensic Sciences and Toxicology, Medical School, University of Crete, 71409 Heraklion, Greece

Correspondence to: Dr John Tsiaoussis, Laboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, Voutes, 71110 Heraklion, Greece, E-mail: tsiaoussis@uoc.gr Professor Aristidis Tsatsakis, Department of Forensic Sciences and Toxicology, Medical School, University of Crete, Voutes, 71409 Heraklion, Greece, E-mail: tsatsaka@uoc.gr *

Co-first authorship

12 2019

03 10 2019

42 6 2228 2244 27082019 01102019

2019

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Colorectal cancer (CRC) is one of the four leading causes of cancer-related mortality worldwide. Even though over the past few decades the global scientific community has made tremendous efforts to understand this entity, many questions remain to be raised on this issue and even more to be answered. Epidemiological findings have unveiled numerous environmental and genetic risk factors, each one contributing to a certain degree to the final account of new CRC cases. Moreover, different trends have been revealed regarding the age of onset of CRC between the two sexes. That, in addition to newly introduced therapeutic approaches for various diseases based on androgens, anti-androgens and anabolic hormones has raised some concerns regarding their possible carcinogenic effects or their synergistic potential with other substances/risk factors, predisposing the individual to CRC. Notably, despite the intense research on experimental settings and population studies, the conclusions regarding the majority of anabolic substances are ambiguous. Some of these indicate the carcinogenic properties of testosterone, dihydrotestosterone (DHT), growth hormone and insulin-like growth factor (IGF) and others, demonstrating their neutral nature or even their protective one, as in the case of vitamin D. Thus, the synergistic nature of anabolic substances with other CRC risk factors (such as type 2 diabetes mellitus, metabolic syndrome and smoking) has emerged, suggesting a more holistic approach.

anabolic agents androgens colorectal cancer testosterone dehydroepiandrosterone vitamin D insulin IGF-1 growth hormone

1. Introduction

Colorectal cancer (CRC) is the fourth most common type of malignancy after breast, lung and prostate cancer, accounting for 49,190 deaths annually in the USA alone (1). Numerous risk factors have been identified, such as age, a family history of CRC, ethnic background (individuals of African descent), a high carbohydrate diet, poor physical activity, obesity and metabolic syndrome, smoking and alcohol abuse (2–5). Originating from epithelial cells at the base of intestinal crypts, the current model of carcinogenesis is that of the adenoma-carcinoma sequence, first described in the 1990s by Bert Vogelstein and Kenneth Kinzler [Fearon and Vogelstein (6) and Kinzler and Vogelstein (7)]. This model proposed a sequential transformation of the normal colorectal epithelium to an adenoma that could further transform into an invasive and metastatic tumor (carcinoma). Mutations in key regions begin to aggregate, turning normal mucosa to an early adenoma and, after a certain point of no return, the accumulated genetic alterations transform it to a carcinoma. Chromosomal instability, microsatellite instability, CpG island methylation and activating oncogenic mutations in genes such as adenomatous polyposis coli (APC), K-ras and p53 are found to play a key role in this sequence (7–9).

However, as it was found thereafter, the Vogelstein model could explain 90–95% of CRC cases. The remaining 5–10% of cases were found to be germline-inherited cancers, such as familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). Notably, 2–3% of all CRC cases are associated with pre-existing inflammation and are referred to as colitis-associated cancer (CAC) (10). In these cases, the activation of nuclear factor (NF)-κB signaling in tumor-associated macrophages (TAMs) leads to the indirect activation of signal transducer and activator of transcription (STAT)3 in pre-malignant intestinal epithelial cells (IECs) (11,12). Even though epidemiologic studies have witnessed a shift towards younger age groups over the past decade, the age group most commonly affected remains that of the middle-aged (>50 years of age) (13), a finding closely related to the Vogelstein model (the accumulation of mutations) (14,15).

Moreover, although CRC is not considered a sex-related malignancy per se, sex differences in incidence rates do exist (16–21). As far as the male population is considered, cancer incidence exhibits two peaks; the first one appears before the age of 35 and the second after the age of 55. On the other hand, in the female population, there is a single peak trend, between 35 and 54 years of age (22,23). Taking into consideration that physical activity performed before or after cancer diagnosis is related to a reduced mortality risk among CRC survivors (24) and is therefore recommended, along with the high prevalence of the use/misuse and abuse of anabolic agents with hormonal activity, such as testosterone, dihydrotestosterone (DHT), finasteride, insulin, insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in the sports community over the past decades (25), a great concern of any possible carcinogenic properties or synergistic effects of the anabolic agents with the already well-studied and identified CRC risk factors has emerged (5). Nonetheless, the data are not consistent: An increasing body of evidence indicates that adequate levels of vitamin D, structurally related to a number of anabolic agents, can indeed protect against carcinogenesis via genomic and non-genomic mechanisms. In addition, the general population experiences uncontrolled multi-chemical exposure from several different sources at doses around or well below regulatory limits (pesticides, food additives, lifestyle products components) (5,15,26) that can contribute to genotoxicity, endocrine disruption, target organ toxicity (3,4,27–29) by affecting systemic mechanistic pathways, such as oxidative stress and cell aging (14,30–32). These, along with the finding that human colorectal adenocarcinomas express specific steroid hormone receptors (33–40), has sparked the interest of the scientific community to unveil any possible pathogenetic mechanisms. Nonetheless, an increasing body of evidence indicates that adequate levels of vitamin D, structurally related to a number of anabolic agents, can indeed protect against carcinogenesis via genomic and non-genomic mechanisms.

2. Androgens

An androgen is considered any molecule capable of inducing and maintaining the male phenotype in an organism (male primary and secondary sexual characteristics and fertility) and taking part in the universal outgrowth of the musculoskeletal system and the anabolic shift of the metabolic status (41). Generally, the androgen-producing endocrine glands are able to synthesize five androgens via a sole pathway: Testosterone, dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), androstenedione and androstenediol, the latter of which has both androgenic and estrogenic properties. The molecules that prevail in this category are testosterone (the principal androgen in mammals) and DHT (potent metabolite of testosterones). In fact, they are the only androgens with direct androgenic activity. Other molecules, such as DHEA, due to their inferior potency, have received less attention. In an adult male organism, testosterone is primarily produced by Leydig cells in the testes. In addition, the extra-gonadal synthesis of testosterone and DHT by the adrenal testosterone precursor, DHEA, also occurs (42). Although adrenal androgens represent a minor fraction of the circulating testosterone for an adult male with an intact androgen biosynthesis cascade, they can be the main androgens in a female or a pre-puberty male (43). In the majority of cases, the classical mode of action of androgen superfamily is mediated by the androgen receptor.

Anabolic androogenic steroids (AAS) are used in the treatment of several disorders, such as hypogonadism, cachexia of various etiologies, hypercalcemia, hypercalciuria, in oncology as a supportive treatment and other chronic diseases (44). Since the early 1930s, AAS have been extensively used by amateur and professional athletes and the general public for the improvement of their physical condition and athletic performance (45–49). When used for ergogenic or recreational purposes, the dose levels are usually 5ement of physical condition and athletic performance (47,50,51). At such supraphysiological levels, AAS can cause a number of severe side-effects, including liver dysfunction, renal disorders, cardiotoxicity and potentially, stroke (52). In addition, anti-androgen therapy is also relatively common, having a wide variety of applications ranging from severe conditions (such as the treatment of prostate cancer and polycystic ovary syndrome) to more benign or even aesthetic conditions (such as acne and male pattern hair-loss). Thus, given their wide use in modern society, it is reasonable to scrutinize whether misbalanced androgen levels may possibly have a direct or indirect connection with CRC (41). In the following paragraphs, the current data regarding androgens and CRC will be presented according to the clinical significance of the studied molecule.

Natural androgens Testosterone

Testosterone, being the most clinically important androgen, has attracted scientific interest from as early as 1986. At that time, studies advocated that androgens played a protective role against CRC. In detail, Izbicki et al (1986) conducted experiments on 40 male rats. They found that chemical castration increased colonic tumor incidence, while testosterone administration following surgical castration produced a borderline statistically significant reduction in tumor incidence (P<0.053), particularly in the right colon (22). In recent years, hypotestosteronemia (defined as levels of testosterone <11 nmol/l or 320 ng/dl) was found to contribute to the development of CRC (53). Further data indicating the protective role of testosterone came from studies on patients who received androgen deprivation treatment for prostate cancer. In detail, it was found that the group with the higher risk of developing CRC was that of the orchiectomized male patients followed by patients receiving gonadotropin-releasing hormone (GnRH) agonist therapy (particularly if the treatment was prolonged) (54). On the contrary, there is evidence to suggest that androgens may act as promoters of colon carcinogenesis (2,55–57). Experiments using genetically modified mice, found that in orchiectomized males, the tumor load was lower when there was no administration of male hormone replacement therapy (2). Other researchers have indicated that, at an early stage, androgens may play an active role in the transition from adenoma to carcinoma (6). In contrast to both previous statements, a large study on 4,165 males aged 70–88 years demonstrated that increased testosterone levels were associated neither with an increased nor with a decreased risk of colon cancer risk (58). The same conclusion was achieved by a prospective study of 8,771 males and females from the general population of Denmark, who were followed-up for >30 years (59). Whichever the case may be, androgens can be related to CRC either through direct mechanisms (mediated through androgen receptors), indirect mechanisms (smoking and alcohol habits, metabolic syndrome and type 2 diabetes mellitus, altered gut microbiota and increased stress hormones) or even a combination of both (60). Worthy of mention is the fact that regardless of the nature of the study (in vitro, in vivo or epidemiological), a common ground has yet to be found given the opposing data derived from these studies. Thus, in order to reach a consensus on the possible carcinogenetic properties of testosterones and the circumstances under which they appear, and to provide the grounds for a safe comparison between studies, research teams will have to adopt a common methodology as the basis of their experiments (27).

DHEA

Despite being less extensively studied, opposing results have been obtained on this less potent molecule as well. In an observational study on 170 individuals, the plasma levels of dehydroepiandrosterone sulfate were shown to be inversely associated with the risk of developing colon cancer (with a borderline statistical significance) (61). Moreover, another study proposed that DHEA strongly blunts serum deprivation-induced apoptosis. The anti-apoptotic effects of DHEA have been found to be completely reversed by testosterone through the blockade of DHEA receptors, thereby antagonizing its actions (62).

Mode of action

There are namely two modes of action, direct action and indirect action. These are discussed below.

a) Direct action: Androgen receptors (ARs)

Steroid hormones, and thus androgens, exert their effects mainly through interactions with specific receptor proteins (37,56). The presence of ARs in human colonic tumors was first shown by Alford et al (34). The gene encoding the AR is located on the X chromosome. It contains two polymorphic trinucleotide repeat segments that encode polyglutamine (CAG) and polyglycine (GGC) (normally, ranging from 6 to 39 repeats). Surprisingly, only the number of CAG repeats has been found to be associated with misbalanced androgen levels. In fact, studies have demonstrated an inverse association between the number of repeats and the risk of prostate cancer (63,64). According to Hoque et al, the number of these repeats is gradually reduced in prostate cancers (65). Existing data advocate that fewer CAG repeats result in a higher transcription activity of AR, a finding positively associated with prostate cancer (66,67). In parallel, a greater number of repeats are associated with increased serum androgen levels, indicating a protective role of these against CRC (61,66).

Notably, Westberg et al came across a sex-related difference in the association between the number of the CAG repeats and the risk of developing CRC. The association was found to be direct in males, but inverse in females. They concluded that the inverse association observed in females would imply a stimulatory rather than inhibitory influence of AR on androgen production. A possible explanation could be found in the implication of both the AR and the estrogen receptor b (ERb) in the regulation of serum androgen levels (68). The above-mentioned hypothesis was reinforced by the similar findings of Slattery et al, who analyzed two large case-control studies of CRC. They further found a greater chance of microsatellite instability (MSI) or p53 mutated tumors in the male population when more CAG repeats were present in the AR gene. Their concern was the lack of a common accepted parameter to determine the regulation of androgen levels. It has not yet been established whether the CAG repeat (as suggested by haplotype analysis of the AR gene) or the functionality of the receptor for the specific polymorphism is the most informative variant (64).

The above-mentioned results are in discordance with a following larger scale study of 1,798 CRC cases and 1,810 controls. In that study, the implication of the AR CAG repeat polymorphism in colorectal cancer prognosis was investigated for the first time. Of note, no association was found between the above-mentioned polymorphism and CRC overall or the disease-specific survival rate. As outlined by the authors, the genotyping error rate calculated from the duplicated samples was relatively high for the AR CAG repeat polymorphism (69). A genotyping error occurs when the genotype of an individual observed in the laboratory does not correspond to the individual's true genotype (70). The causes could be categorized as a variation of the DNA sequence, the low quantity or quality of DNA, biochemical artifacts (low quality reagents, poor equipment precision or reliability, Taq polymerase errors, the lack of specificity, electrophoresis artifact) and human error (sample manipulation, experimental error, data handling) (71). Since the main cause of genotyping error is human error (71), Rudolph et al concluded that further studies are required to extract solid results (69).

Further attempts to unveil a possible prognostic value of the AR CAG repeat sequence with regards to sex differences have yielded some interesting findings. A recent case-control study of 550 CRC cases and 540 healthy controls concluded that long CAG repeats confer an increased risk of developing CRC in both sexes along with a poor 5-year survival, while fewer CAG repeats seem to protect against CRC (72). Previous studies have indicated that the CAG repeat length of AR inversely affects its transactivation potential, either through directly altering the receptor's function (73) or indirectly reducing AR messenger in RNA and protein levels (74). Either way, long CAG repeat sequences lead to absence of AR expression, which, in turn, has been linked to tumor size >5 cm in diameter and moderate to poor differentiation (at T3-T4 and N1-2 stages). These patients have also demonstrated a great risk of recurrence or metastasis. Notably, the above are found less frequently when there are short CAG repeat sequences and, thus, the normal expression of AR (72).

It should be pointed out that the trans-activating function of AR is dependent on its ligands, the androgens. The receptor participation in controlling cellular differentiation and proliferation in hormone-dependent tissues does not always occur in the same manner (75). Catalano et al shed some light onto this phenomenon. They mentioned two isoforms of the AR; androgen receptor A (AR-A) (87 kDa) and androgen receptor B (AR-B) (110 kDa). In the healthy colonic mucosa, both receptors are present; however, in the neoplastic colonic mucosa, only AR-A could be detected. The loss of expression of AR-B and the continuous expression of AR-A was proposed to indicate a loss of cell differentiation (76).

Another category of AR was also discovered; the membrane androgen receptors (mARs). Normally, the actions of the androgens are mediated through intracellular receptors (iARs). mARs seem to mediate opposite actions than iARs, inducing tumor regression (77). Furthermore, the affinity and selectivity of mARs differ among specific androgens (78). Through this receptor, testosterone exerts pro-apoptotic effects in both prostate and colon cancer cells. In human colon cancer cell lines, the activation of the ligand-bound androgen receptor suppresses the transcription of β-catenin. Consequently, there is a decreased expression of β-catenin target oncogenes, including cyclin D1 (79).

The long-term activation of mAR by testosterone-albumin conjugated (TAC) treatment has also been linked to the dephosphorylation of protein Kinase B (Akt) both in vitro and in vivo (77). It is closely connected with the invasiveness of colon cancer cells in response to a variety of stimuli [heregulin, P21 (RAC1) activated kinase 1 (PAK1), Sprouty-2 etc.] (80–82), a finding supported through the examination of the upstream regulators of Akt, in particular PI3K. Upon long-term TAC treatment, it is dephosphorylated, leading to reduced cell motility in colon cancer and, consequently, invasiveness. Of note, although testosterone seems to induce p-Akt downregulation when it binds to mARs, iAR bondage induces p-Akt upregulation, even within the same cells. The main target of mAR activation that may regulate cell motility is thought to be vinculin; a cytoskeletal protein which links integrin adhesion molecules to actin. The inhibition or silencing of vinculin via the phosphorylation by specific inhibitors, as is the case with activation of mARs, largely reverses both actin reorganization and the inhibition of migration (77). An illustrated representation of the mode of action of mAR is presented in Fig. 1.

Upstream in the AR activation pathway, the role of co-activator-associated arginine methyltransferase 1 (CARM1) is crucial. CARM1 is a protein with arginine-specific histone methyltransferase activity. It primarily binds to the histone and p160 co-activators, leading to the activation of nuclear receptors, ARs included. Thus, it promotes nuclear receptor activity and acts as a molecular switch for gene-specific transcription factors including p53, NF-ĸB, lymphoid enhancer-binding factor 1 (LEF1)/transcription factor 4 (TCF-4) and E2Fs (83,84). Taking the above into consideration, it is clear that the role of CARM1 is of utmost importance for cell proliferation and survival (85,86). Kim et al reported the overexpression of CARM1 in CRC specimens, but a weak expression in normal mucosal cells. They demonstrated that CARM1 inhibits the p53 response and instead promotes the NF-ĸB response in Caco2 cells (87). However, the mechanisms involved remain to be fully clarified (87,88).

b) Indirect mode of action

Decreased levels of androgens seem to lead to a net increase in stress hormone levels, such as cortisol, which affect the tumor environment (89). The involvement of the innate immune system in the development of CRC has been demonstrated as well. The neutrophil count is reduced, as found by Chuang et al in castrated males, although it can be restored to normal levels through androgen supplementation (90). Androgens also seem to affect the production and excretion of biliary steroids and bile, compounds that are suggested to act as co-carcinogens (17,38). Lastly, an induction of insulin resistance following androgen deprivation therapy (91) has been linked to increased risk of developing CRC (92). The connection between insulin and CRC will be further discussed.

Synthetic anabolic agents

Synthetic anabolic agents are categorized into two categories: Anabolic-androgenic steroids (AAS) and selective androgen receptor modulators (SARMs) (93). The AAS molecules that have thus far been approved as therapeutic agents are testosterone, nortestosterone, dihydrochlormethyltestosterone (DHCMT), metenolon, metandienone, methyltestosterone, oxandrolone, fluoxymesterone, stanozolol, formestane, 5on, metandieno (94). SARMS are non-steroidal alternatives to AAS with the selective activation of the AR in either muscle tissue or bones (93).

A number of adverse effects of these compounds have been described when used either as medicine or as doping agents. As far as AAS's relation to cancer is concerned, a positive association with hepatocellular carcinoma (95), renal cancer (96–98), soft tissue carcinoma (99), adenocarcinoma (100,101) and lymphosarcoma (102) has been found, along with a case report hypothesizing their involvement in leiomyosarcoma (103). SARMs have also been linked to prostate cancer (104). However, to the best of our knowledge, there are currently no data available in the current literature associating any of these compounds with CRC.

3. Anabolic hormones <sec> <title>Insulin and insulin receptors (IRs)

Insulin is one of the principal anabolic hormones in the majority of animals since it regulates the metabolism of almost all key energy points in favor of their synthesis and storage. The target substances of insulin k are namely carbohydrates, lipids and proteins. Acting on adipocytes, hepatocytes and muscle cells, induces and maintains to a certain extent, an anabolic state which is described by the synthesis of carbohydrates, fatty acids and proteins, while reducing their degradation. Although a basic requirement is the prior balance between the circulating levels of the target substances and the intracellular ones, for a short period of time, it can overcome the concentration gradient of a substance and induce its endocytosis (105). The role of insulin in CRC was first introduced by the observation that obesity was associated with an increased risk of developing CRC in males. Subsequently, hyperinsulinemia and insulin resistance were linked to obesity and CRC development (106). In a large epidemiological study of almost 25,000 patients with type 2 diabetes mellitus (107) and in a large meta-analysis of 16 studies (108), a direct association between long-term insulin therapy and type 2 diabetes mellitus with an increased risk of developing CRC was found. It has also been established that CRC survivors with excess amounts of blood insulin have a greater risk of recurrence (109). By contrast, a large registry-based study in Connecticut that included 9,395 patients with CRC (110) and a smaller Norwegian study of 1,194 hospitalized patients with CRC (111), failed to find an association between diabetes and CRC-specific death. It must be stated though, that the latter studies included patients with metastatic CRC as well.

Schoen et al found a statistically significant association between insulin and adenoma status. The association was even stronger with advanced adenomas. The association with adenomatous polyps, the precursor of CRC, confirms a link between insulin and early neoplasia (112). It must be kept in mind that high insulin levels increase serum IGF-1 levels (113,114), a factor which is closely related to carcinogenesis.

To date, two isoforms of IR have been described, differing at the short exon 11 (encodes 12 amino acids). The absence of exon 11 transcripts the IR-A (short isoform), while its presence the IR-B (long isoform) (115). Existing evidence supports that the two IR isoforms play different biological roles. IR-A mostly exerts mitogenic effects and IR-B modulates cell metabolism (116). Abbruzzese et al found a strong IR expression in adenomas and low-grade adenocarcinomas (117). The expression of IR-A has been found in cells that have lost their differentiation, a finding which is in accordance with the presence of this receptor in cancer (118,119).

The expression of IR is mainly considered to be present in epithelial tumor cells [epithelial insulin receptor (EIR)]. However, Heckl et al found the expression of the receptor in other tumor compartments, e.g., the tumor-vasculature [vascular insulin receptor (VIR)]. When 1,580 cases of CRC were examined concerning the expression of the IR, differential expression patterns of the IR in tumor cells (EIR) and endothelial cells of tumor vessels (VIR) have been observed. EIR expression is strongly associated with distant metastasis, lymphatic invasion, lymph node metastasis, tumor-specific survival (TSS) and overall survival (OS). Moreover, EIR has been found almost exclusively in the cytoplasm of tumor cells, whereas a (simultaneous) membranous IR expression was less prevalent (120). These findings were further clarified by in vitro experiments by Morcavallo et al, who demonstrated that insulin or IGF-II stimulation induced the phosphorylation-activation of IR-A, which was then internalized from the cell surface. The underlying mechanism was speculated to be a sustained phosphorylation of the receptor, leading to prolonged activation (121).

On the other hand, VIRs are thought to contribute to neovascularization following abduction by elevated insulin levels. VIRs are frequently found in CRC, particularly in left-sided CRCs, and they are significantly associated with tumor invasiveness (120).

From another point of view, insulin resistance in vascular endothelial cells can promote tumor formation, possibly through mechanisms involving chronic inflammation (122). This resistance is characteristic of endothelial dysfunction in obesity and type 2 diabetes (123–126) and was found to promote tumor development. By contrast, there was almost no effect of insulin signaling on intestinal carcinogenesis through epithelial receptors (122).

In order to fully understand the role of insulin in the tumor cascade, special reference must be made to extracellular vesicles (EVs). These are vesicles found in the extracellular space of various cell types. They can be found under normal and pathological conditions (127,128). EVs package biologically active content (including proteins, mRNA and miRNA), which they further transfer to the recipient cells. Due to their action they are considered as mediators of signaling cascades (129,130). EVs are known to mediate various biological cascades relative to cancer, such as the activation of Wnt signaling and the activation of PI3K/Akt signaling (129).

Insulin, similar to other growth factors, induces PI3K/Akt signaling (131–133). PI3K/Akt-positive CRC cells react to PI3K/Akt signaling by producing EVs which, in turn, amplify the proliferative signal in other CRC cells in the close environment. The deeper in the proliferative core the EVs reach, the greater the benefit for the tumor, as in these areas the transfer of nutrients/growth factors would have been otherwise impossible. Thus, EVs amplify the proliferative signal and aid cancer progression (134).

IGF and its receptor (IGF-R)

IGF is a hormone that serves as the mediator of growth hormone (GH)-stimulated somatic growth, as well as a mediator of GH-independent anabolic responses in a number of cells and tissues, while it is also associated with mitogenesis, cell survival and differentiation (135–142). In detail, IGF-1 promotes cell cycle progression and inhibits apoptosis either by triggering other growth factors or by interacting with pathways which have an established role in carcinogenesis and cancer promotion (142). Ma et al stated that there is an increase in IGF-1 levels in patients with CRC (143), while other studies have advocated the overexpression of IGF-R, as well (144–147). In accordance with this, several studies have linked elevated plasma IGF-1 and IGF-1R downstream signaling to an enhanced risk of colorectal neoplasia and a poor survival (148–152). Furthermore, Peters et al found that IGF-1 was closely related to the expression of the proliferation marker Ki-67 (153). Ki-67 is a nuclear protein that is active only in dividing cells and absent in cells locked in G0 phase. This is a logical outcome when taking into consideration that IGF-1 can stimulate the expression of cyclin D1, a molecule that accelerates the progression of the cell cycle from G1 to S phase (154). However, there is no prognostic relevance of Ki-67 in CRC, regardless of the stage of disease (155,156). Through a reverse line of thought, octreotide, a molecule that lowers the IGF-1 concentration, has been shown to attenuate the growth rate of tumor cells in vivo (157).

The expression of IGF-2 is also highly associated with tumor stage. The association was speculated when it was found that autocrine IGF-2 production and consequent IGF-R activation increased tumor growth and reduced apoptosis (153). Thus, it is plausible that, when IGF-1 or IGF-2 is present, an IGF-1R self-stimulation will produce an autocrine/paracrine loop in CRC. However, no prognostic effect of IGF-1 and IGF-2 has been proven (153).

A family of six circulating proteins termed insulin-like growth factor binding proteins (IGFBPs) has been found to interfere with the action of IGF. Thus, their involvement in CRC must be investigated, as well. They act either as tumor suppressors by limiting IGFs activity (158) or as inhibitors of cancer growth through IGF-independent mechanisms (159). High IGFBP2 plasma levels were found by Liou et al to be independently associated with a reduced overall survival (OS) of patients with CRC (160). By contrast, IGFBP3 has been shown to be inversely associated with CRC, as its plasma levels were found to be lower in those patients (143). Notably, IGFBP-3 can either oppose or enhance the biologic action of IGF-I through direct bondage to IGF-I or indirectly to IGF-R (161).

In a prospective cohort study of 210 patients with CRC, IGF-1 expression was shown to be closely associated with tumor size and the depth of invasion. However, it was stated that a shift of investigation towards the IGF-1/IGFBP-3 ratio is warranted, as it better describes the biological effects of IGF-1 (152). A nested case control study of males in the Physician's Health Study demonstrated an increased risk of CRC in subjects with high IGF-I levels. The risk was decreased when high IGFBP-3 levels were measured (143). A study of 460 patients was carried out to further examine the association between IGF-I and the IGF-I/IGFBP-3 ratio with colorectal adenomatous polyps. A statistically significant positive association was found, with greater odds ratio when the case group was limited to advanced adenomas. This finding indicates a possible stimulation of non-advanced adenomas towards advanced adenomas (112).

Closer attention must be paid to the IGF-R, as it has been stated that it contributes to resistance to cytotoxic (162), radiation (163) and targeted therapies (164–166). Indeed, the silencing of the receptor increases the intracellular drug concentration (such as oxaliplatin and vincristine); an effect mediated via the PI3K/Akt pathway (167). A progressive increase in IGF-1R expression occurs in normal colonic mucosa, while it transits to adenomatous, as well as in the transition from adenomatous to carcinomatous tissue (147). Peters et al have confirmed a strong expression of the IGF-1 receptor in >99% of all CRC cell lines of their experiments (153).

Following its activation, IGF-R induces multiple intracellular mechanisms, as shown in Fig. 2. It induces the transcription of the vascular endothelial growth factor (VEGF) gene (168,169), upregulates the anti-apoptotic protein, Bcl-xL (170) and inhibits the action of β-catenin (through PI3K/Akt activation) (171). From another perspective, Nahor et al demonstrated that the tumor-suppression genes p63 and p73 inhibit the IGF-1R promoter, reducing the endogenous IGF-1R levels in a dose-dependent manner. Through this mechanism, it was proposed that they control colon cancer proliferation (172).

The pro-oncogenic activities of IGF-1R are solely mediated through its proximal downstream effectors: Insulin receptor substrate 1 (IRS-1) and 2 (IRS-2) (173,174). IRS-1 expression appears to be inversely associated with CRC differentiation. However, it may be upregulated in both primary and metastatic human CRC, a finding that has not been observed in normal colonic epithelium (175). It has been further supported that the upregulation of IRS-1 can occur directly from androgens (64). IRS-2 mRNA and protein expression have a positive association with the transition from normal colorectal epithelium to adenoma and adenocarcinoma. Furthermore, IRS-2 overexpression promotes the invasiveness of CRC cells. It activates the oncogenic PI3K/Akt pathway and at the same time reduces cell adhesion (176). Finally, IRS-1 and IRS-2 polymorphisms have been independently associated with the risk of developing CRC in a direct manner (177).

The above-mentioned findings are further supported by the action of NT157 in murine and human CRC cells. NT157 is a molecule that, through bondage to an allosteric site of the IGF-1R, it induces a conformational change. As a result, the receptor is dissociated from IRS1 and IRS2 proteins. Consequently, IGF-1R stronger interacts with the adaptor protein Shc, leading to an enhanced activation of extracellular signal-regulated kinase (ERK). Indeed, experiments have confirmed that NT157 activates ERK1/2, without activating Akt (178).

Vitamin D

Vitamin D regulates cellular functions, such as differentiation and proliferation in normal and malignant tissues. It also regulates cell adhesion in tumor cells and modifies tumor angiogenesis, invasion and metastasis along with decreasing oxidative DNA damage (179). Vitamin D deficiency has been associated with various cancer types (180,181).

Vitamin D first attracted scientific attention after an inverse association was observed between solar UV-B exposure and CRC incidence in both genres (182). As it has been well-established, UV-B radiation is essential for the production of vitamin D3, which after two steps becomes 1,25-(OH)₂-vitamin D (calcitriol), the most active component (183,184).

The study by Boscoe and Schymura on 3.1 million individuals from the northern part of the USA supported that low levels of vitamin D can induce the progression of CRC, although no association was found with disease onset. Their proposal was based upon a higher death rate which occurred during the winter months (when levels of vitamin D are markedly reduced) (182). Feskanich et al found an inverse association of 25-OH-vitamin D and CRC in observation in the female population, although only in areas where high levels of UV-B are available (185). In fact, levels of 25-OH-vitamin D >20 ng/ml have been advocated to provide protection against CRC (186). If levels of 25-OH-vitamin D are >82 ng/ml, then it is estimated that the cancer incidence is decreased by 50% (187). However, no association has been found between 1,25-OH₂-vitamin D and CRC (185); a finding disputing the results of two previous studies (188,189).

Calcitriol has been found to reduce tumorigenesis in rats (190,191) and proliferation in both normal and premalignant human rectal epithelioma (192), as well as in human colorectal cell lines, while it stimulates their differentiation (193–196). Vandewalle et al proposed that an increased expression of vitamin D receptor (VDR) may lead to cell differentiation and growth inhibition either through calcitriol or through non-calcemic analogs (195). The mechanisms behind the protective role of vitamin D against CRC are multiple and can be categorized into genomic and non-genomic mechanisms, as discussed below.

Genomic mechanisms

The genomic mechanisms are mediated through the VDR as is shown in Fig. 3. Following the bondage of 1,25-OH₂-vitamin D to the receptor, the complex is dimerized with another receptor, the retinoid X receptor (RXR). This heterodimer targets specific areas in genes called vitamin D response elements (VDREs) (197). As a result, several miRNAs are affected through up- or down-regulation. These miRNAs have been speculated to suppress oncogenes or enhance the expression of tumor suppressor genes. For example, vitamin D can induce the promoter of miR-627. This gene has been inversely linked with CRC, as its decreased expression (an aftermath of reduced levels of vitamin D) has been found to promote cancer (198).

Further action of vitamin D in human colon tumor cells leads to the upregulation of the potent anti-angiogenic factor, thrombospondin 1 (199). The upregulation of the transcription of the Wnt-inhibitors, the DICKKOPF-1 and DICKKOPF-4 genes, has also been linked with the action of calcitriol (200). There are data to suggest that calcitriol regulates apoptosis as well (201). Following treatment of colorectal cell lines with 1,25-OH₂-vitamin D, it was found that apoptosis was triggered through secreted protein acidic and rich in cysteine (SPARC)-induced VDR synthesis (202). In another cell line, treatment with calcitriol induced the mRNA expression of the pro-apoptotic protein, G0S2 (G0/G1 switch gene) (203). Furthermore, WAF1 and KIP1 were found to be up-regulated, leading to cell-cycle arrest in G1 phase (201,204,205).

Other studies have demonstrated the effects of calcitriol on tumor growth. Through the induction of cyclin-dependent kinase inhibitors, such as p21, p27 and cystatin D and the inhibition of pro-proliferative genes, including c-my and cyclin D1, tumor growth is halted (198). NF-κB is another target family of genes (fundamental for the cancer cell survival) which are downregulated by vitamin D (206). Finally, the reduction of colon cancer cell lines has been suggested following the decreased expression of Toll-like receptor (TLR)2 and 4 on human monocytes (207).

Non genomic mechanisms

Apart from the genomic action through the nuclear receptor, calcitriol can bind to membrane receptors in certain tissues (including the intestines), leading to non-genomic, non-nuclear actions (208–211). It has been well documented that in CRC, APC mutation is by far one of the most common, allowing various downstream pro-oncogenic pathways to upshift. One of these pathways is the Wnt pathway, where β-catenin acts as a transcriptional co-regulator, cooperating with transcription factors of the T-cell factor (TCF) family to determine gene expression (212,213). Pendás-Franco et al described the protective action of calcitriol in colon cancer cells, according to which it induces VDR to bind with β-catenin and restrain it from translocating to the nucleus and inducing the expression of pro-carcinogenic genes (200). Furthermore, vitamin D-related compounds have been found to induce the production of IGFBP-5. These molecules bind both with IGF-1 and IGF-2, suppressing the stimulating effect of these molecules (214).

Furthermore, vitamin D seems to be able to reprogram the tumor-associated macrophages (TAMs) in a manner that halts their tumor-promoting actions (215), probably by inhibiting STAT1 activity. As a result, there is no production of interleukin (IL)-1 from the latter, rendering the tumor colon cells sensitive to apoptosis through the TRAIL pathway (216). In parallel, due to the lack of IL-1β expression, the Wnt pathway is deactivated (215).

Further observations of a crosstalk between vitamin D and TGF-β1/SMAD1 signaling in the growth inhibition of human colon cancer-derived cells has shown that this interaction halts tumor growth by blocking the expression of cell cycle proteins and inhibiting the action of cyclins D1, D2, D3 and E (217). It has also been found to inhibit mitogenic Ras signaling, as well as the epidermal growth factor (EGF) (218–220). Furthermore, Ben-Shoshan et al exhibited an inhibition of vascular endothelial growth factor (VEGF) in colon cancer cell lines by vitamin D (221).

Last but not least, the association of vitamin D with calcium must be examined. It seems they exert a synergistic effect in reducing CRC incidence. This was first described in Apcmin mouse models by Harris and Go (222) and later on by Lappe et al who carried a clinical trial on post-menopausal women in Nebraska. They concluded that although calcium alone reduced the all-cancer incidence by 44%, when accompanied by vitamin D the reduction reached 77% (223).

Growth hormone (GH)

Human growth hormone (hGH) or somatotropin, is a peptide-hormone secreted mainly by somatotropic cells within the lateral wings of the anterior pituitary. After entering the bloodstream it reaches its target organs (namely the liver, muscles, bones and adipose tissue) binding to its receptor [growth hormone receptor (GHR)] and thus inducing its anabolic properties through the activation of the mitogen activated protein kinase (MAPK)/ERK and JAK/STAT pathways (224,225). It has been well documented that GH plays a key role in longitudinal growth during childhood, while maintaining various important metabolic functions throughout life (promoting lipolysis, protein synthesis and gluconeogenesis, while reducing glucose uptake from the liver) (226). Of note though, GH action is slightly more sophisticated. Apart from its direct action, an indirect one through the production of IGF-1 also takes place, representing an important part of GH physiology. In fact, a potent stimulus of IGF-1 production is the GH per se. Moreover, the tissues producing IGF-1 (the liver 75% and the peripheral tissues) are indeed the target organs of GH (227). However, it has been proven that GH is not only synthesized in the pituitary, but also in various other tissues, such as the large intestine, prostate and breast (228,229). In this case however, GH lacks the endocrine potential and its action is mainly restricted to an autocrine or paracrine manner (230).

Due to its proliferative properties, GH has attracted reasonable attention for its carcinogenic potential. In fact, various studies have demonstrated that GH is indeed able to create a favorable microenvironment for tumor cells. In detail, GH overexpression is linked to an increased risk of malignancies (231), while its downregulation is linked to a carcinoprotective state. As for CRC risk per se, GH has been proven to act as a tumor promoter in colon tissue by suppressing p53 (232), phosphatase and tensin homolog (PTEN) and APC (8), while it has also been proven that colon cancer cells overexpress GHR (232). In fact, upregulated GH has been exhibited to increase ERK phosphorylation and to decrease APC expression (232). It is known that a decreased APC expression promotes the nuclear accumulation of β-catenin, which in turn increases Wnt signaling through the activation of pro-proliferative genes (233,234). Thus, even though it is difficult to estimate the exact concentration for any given age above which GH poses its carcinogenic effect on colon cells, there is enough evidence supporting that the ability of GH to change the microenvironment of tumor cells can have a synergistic effect with other CRC risk factors (such as intestinal dysbiosis, smoking etc.), shifting the balance towards tumor survival and proliferation (235).

4. Conclusions

After 30 years of intense research on CRC and its biological behavior, only few facts have withstood the test of time, all revealing the impressive complexity and diversity of this entity. In fact, this is the case for the association between CRC and anabolic substances. Driven by epidemiological observations on both sexes, a time pattern of CRC onset has been found. However, studies thus far have failed to reach a consensus regarding the direct connection between androgens and the risk of developing CRC, as some studies have indicated a negative effect, while others have pointed out a neutral or even a protective one (Table I). In the case of androgens, the androgen receptor (the principal mediator of their action) has been proven to be altered in CRC in contrast to healthy individuals. Moreover, anabolic substances are also put to scrutiny given the intense presence of such substances in patients with CRC (namely IGF-1). However, no direct or well-studied indirect mode of action on CRC pathogenesis has been found for both classes. Thus, more studies are needed that will focus on both epidemiologic data (that will try to investigate how the use of anabolic agents, androgens included, alters CRC statistics) and the elucidation of molecular pathways implicated in CRC, in order to allow the extraction of solid conclusions. In addition, as passive everyday life exposure to hazardous chemicals could affect traditional clinical risk factors and act synergistically, the patterns of living and consumers' trends should also be taken into consideration when evaluating CRC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

JT conceived and designed the study. TK and TKN researched the literature, performed analysis of data and drafted the manuscript. DAS, CT and AT made substantial contributions to the conception of the study and critically revised the article for important intellectual content. MS, JS, TMS made substantial contributions to the design of the study and critically revised the article for important intellectual content. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

Abbreviations

CRC

colorectal cancer

DHT

dihydrotestosterone

IGF

insulin-like growth factor

FAP

familial adenomatous polyposis

HNPCC

hereditary non-polyposis colorectal cancer

CAC

colitis-associated cancer

TAMs

tumor-associated macrophages

STAT3

signal transducer and activator of transcription 3

IECs

intestinal epithelial cells

growth hormone

DHEAS

dehydroepiandrosterone sulfate

DHEA

dehydroepiandrosterone

GnRH

gonadotropin-releasing hormone

ARs

androgen receptors

AAS

anabolic-androgenic steroids

SARMs

selective androgen receptor modulators

insulin receptor

EIR

epithelial insulin receptor

VIR

vascular insulin receptor

IGF-R

insulin-like growth factor receptor

IGFBPs

insulin-like growth factor binding proteins

VDR

vitamin D receptor

VEGF

vascular endothelial growth factor

EGF

epidermal growth factor

RXR

retinoid X receptor

VDREs

vitamin D response elements

References 1

Roshan

Tambo

Pace

The role of testosterone in colorectal carcinoma: Pathomechanisms and open questions

EPMA J7222016

10.1186/s13167-016-0071-5

27833666

5103431

Amos-Landgraf

Heijmans

Wielenga

Dunkin

Krentz

Clipson

Ederveen

Groothuis

Mosselman

Muncan

Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones

Proc Natl Acad Sci USA11116514165192014

10.1073/pnas.1323064111

25368192

Docea

Goumenou

Calina

Arsene

Dragoi

Gofita

Pisoschi

Zlatian

Stivaktakis

Nikolouzakis

Adverse and hormetic effects in rats exposed for 12 months to low dose mixture of 13 chemicals: RLRS part III

Toxicol Lett31070912019

10.1016/j.toxlet.2019.04.005

30999039

Tsatsakis

Docea

Calina

Buga

Zlatian

Gutnikov

Kostoff

Aschner

Hormetic Neurobehavioral effects of low dose toxic chemical mixtures in real-life risk simulation (RLRS) in rats

Food Chem Toxicol1251411492019

10.1016/j.fct.2018.12.043

30594548

Tsatsakis

Kouretas

Tzatzarakis

Stivaktakis

Tsarouhas

Golokhvast

Rakitskii

Tutelyan

Hernandez

Rezaee

Simulating real-life exposures to uncover possible risks to human health: A proposed consensus for a novel methodological approach

Hum Exp Toxicol365545642017

10.1177/0960327116681652

28539089

Fearon

Vogelstein

A genetic model for colorectal tumorigenesis

Cell617597671990

10.1016/0092-8674(90)90186-I

2188735

Kinzler

Vogelstein

Lessons from hereditary colorectal cancer

Cell871591701996

10.1016/S0092-8674(00)81333-1

8861899

Vogelstein

Kinzler

Cancer genes and the pathways they control

Nat Med107897992004

10.1038/nm1087

15286780

Nikolouzakis

Vassilopoulou

Fragkiadaki

Mariolis Sapsakos

Papadakis

Spandidos

Tsatsakis

Tsiaoussis

Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review)

Oncol Rep39245524722018

29565457

5983921

Terzic

Grivennikov

Karin

Inflammation and colon cancer

Gastroenterology13821012114.e52010

10.1053/j.gastro.2010.01.058

20420949

Greten

Eckmann

Greten

Park

Egan

Kagnoff

Karin

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer

Cell1182852962004

10.1016/j.cell.2004.07.013

15294155

Grivennikov

Karin

Terzic

Mucida

Vallabhapurapu

Scheller

Rose-John

Cheroutre

Eckmann

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

Cancer Cell151031132009

10.1016/j.ccr.2009.02.003

19185845

2667107

Chlebowski

Wactawski-Wende

Ritenbaugh

Hubbell

Ascensao

Rodabough

Rosenberg

Taylor

Harris

Chen

Women's Health Initiative Investigators

Estrogen plus progestin and colorectal cancer in postmenopausal women

N Engl J Med35099110042004

10.1056/NEJMoa032071

14999111

Tsoukalas

Fragkiadaki

Docea

Alegakis

Sarandi

Thanasoula

Spandidos

Tsatsakis

Razgonova

Calina

Discovery of potent telomerase activators: Unfolding new therapeutic and anti-aging perspectives

Mol Med Rep20370137082019

31485647

6755196

Tsatsakis

Docea

Tsitsimpikou

New challenges in risk assessment of chemicals when simulating real exposure scenarios; simultaneous multi-chemicals' low dose exposure

Food Chem Toxicol961741762016

10.1016/j.fct.2016.08.011

27515866

Potter

McMichael

Large bowel cancer in women in relation to reproductive and hormonal factors: A case-control study

J Natl Cancer Inst717037091983

6578365

McMichael

Potter

Reproduction, endogenous and exogenous sex hormones, and colon cancer: A review and hypothesis

J Natl Cancer Inst65120112071980

7001123

Young

JrAsire

Polalack

SEER Program: Cancer incidence and mortality in the United States: 1973–1976

US Department of Health, Education, and Welfare, NCI671978

Burbank

Patterns in cancer mortality in the United States: 1950–1967

Natl Cancer Inst Monogr7115941971

5139289

Haenszel

Correa

Cancer of the colon and rectum and adenomatous polyps. A review of epidemiologic findings

Cancer2814241971

10.1002/1097-0142(197107)28:1<14::AID-CNCR2820280105>3.0.CO;2-I

5110624

Howell

The association between colorectal cancer and breast cancer

J Chronic Dis292432611976

10.1016/0021-9681(76)90078-3

1270572

Izbicki

Wambach

Hamilton

Harnisch

Hogenschurz

Izbicki

Kusche

Androgen receptors in experimentally induced colon carcinogenesis

J Cancer Res Clin Oncol11239461986

10.1007/BF00394937

2942549

Nikolouzakis

Stivaktakis

Apalaki

Kalliantasi

Sapsakos

Spandidos

Tsatsakis

Souglakos

Tsiaoussis

Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer

Oncol Lett17270327122019

30854044

6365930

Qiu

Jiang

Zhou

Physical activity and mortality in patients with colorectal cancer: a meta-analysis of prospective cohort studies

Eur J Cancer PrevApril52019

10.1097/CEJ.0000000000000511

30964753

6422758

Gabrielsen

Najari

Alukal

Eisenberg

Trends in Testosterone Prescription and Public Health Concerns

Urol Clin North Am432612712016

10.1016/j.ucl.2016.01.010

27132584

Georgiadis

Tsarouhas

Tsitsimpikou

Vardavas

Rezaee

Germanakis

Tsatsakis

Stagos

Kouretas

Pesticides and cardiotoxicity

Where do we stand? Toxicol Appl Pharmacol3531142018

10.1016/j.taap.2018.06.004

29885332

Margina

Nițulescu

Ungurianu

Mesnage

Goumenou

Sarigiannis

Aschner

Spandidos

Renieri

Hernández

Tsatsakis

Overview of the effects of chemical mixtures with endocrine disrupting activity in the context of real life risk simulation (RLRS): an integrative approach (Review)

World Acad Sci J (In press)

Veremchuk

Tsarouhas

Vitkina

Mineeva

Gvozdenko

Antonyuk

Rakitskii

Sidletskaya

Tsatsakis

Golokhvast

Impact evaluation of environmental factors on respiratory function of asthma patients living in urban territory

Environ Pollut2354894962018

10.1016/j.envpol.2017.12.122

29324378

Zafiropoulos

Tsarouhas

Tsitsimpikou

Fragkiadaki

Germanakis

Tsardi

Maravgakis

Goutzourelas

Vasilaki

Kouretas

Cardiotoxicity in rabbits after a low-level exposure to diazinon, propoxur, and chlorpyrifos

Hum Exp Toxicol33124112522014

10.1177/0960327114532384

24818614

Tsatsakis

Docea

Constantin

Calina

Zlatian

Nikolouzakis

Stivaktakis

Kalogeraki

Liesivuori

Tzanakakis

Genotoxic, cytotoxic, and cytopathological effects in rats exposed for 18 months to a mixture of 13 chemicals in doses below NOAEL levels

Toxicol LettSep122019(Epub ahead of print)

10.1016/j.toxlet.2019.09.004

6684055

Ozcagli

Kara

Kotil

Fragkiadaki

Tzatzarakis

Tsitsimpikou

Stivaktakis

Tsoukalas

Spandidos

Tsatsakis

Stanozolol administration combined with exercise leads to decreased telomerase activity possibly associated with liver aging

Int J Mol Med424054132018

29717770

5979936

Kadıoğlu

Taçoy

Özçağlı

Okyay

Akboğa

Çengel

Şardaş

The role of oxidative DNA damage and GSTM1, GSTT1, and hOGG1 gene polymorphisms in coronary artery disease risk

Anatol J Cardiol169319382016

27182613

5324912

McClendon

Appleby

Claudon

Donegan

DeCosse

Colonic neoplasms: Tissue estrogen receptor and carcinoembryonic antigen

Arch Surg1122402411977

10.1001/archsurg.1977.01370030012002

843213

Alford

Geelhoed

Tsangaris

Lippman

Steroid hormone receptors in human colon cancers

Cancer439809841979

10.1002/1097-0142(197903)43:3<980::AID-CNCR2820430329>3.0.CO;2-R

427738

Sica

Contieri

Nola

Bova

Papaleo

Puca

Estrogen and progesterone binding proteins in human colorectal cancer. A preliminary characterization of estradiol receptor

Tumori673073141981

10.1177/030089168106700407

7314260

Odagiri

Jibiki

Demura

Shinozaki

Nakamura

Demura

Suzuki

Steroid receptors and the distribution of IR-carcinoembryonic antigen in colonic cancer

Dis Colon Rectum277877911984

10.1007/BF02553940

6499618

Jacobson

Present status of steroid hormone receptor in large bowel cancer

Prog Cancer Res Ther293671984

Izbicki

Schmitz

Hoppen

Izbicki

Troidl

Effects of steroid hormone therapy on primarily xenotransplanted human colorectal adenocarcinomas

J Cancer Res Clin Oncol1083453501984

10.1007/BF00390470

6511808

Wobbes

Beex

LVAM

Koenders

AMJ

Estrogen and progestin receptors in colonic cancer?

Dis Colon Rectum275915921984

10.1007/BF02553846

6468198

Bucci

Salfi

Meraviglia

Delric

Hormonal receptors in colorectal cancers (abstract)

Second European Conference on Clinical Oncology and Cancer Nursing841981983

Handelsman

Androgen Physiology, Pharmacology and Abuse

Endotext [Internet]Feingold

Anawalt

Boyce

MDText.com, Inc.

South Dartmouth, MA

2000

Hiort

Holterhus

Nitsche

Physiology and pathophysiology of androgen action

Baillieres Clin Endocrinol Metab121151321998

10.1016/S0950-351X(98)80495-3

9890064

Guyton

Hall

Textbook of medical physiology

11th

Elsevier Saunders

Philladelphia, PA

2006

Brenu

McNaughton

Marshall-Gradisnik

Is there a potential immune dysfunction with anabolic androgenic steroid use?: A review

Mini Rev Med Chem114384452011

10.2174/138955711795445907

21443507

Tsarouhas

Kioukia-Fougia

Papalexis

Tsatsakis

Kouretas

Bacopoulou

Tsitsimpikou

Use of nutritional supplements contaminated with banned doping substances by recreational adolescent athletes in Athens, Greece

Food Chem Toxicol1154474502018

10.1016/j.fct.2018.03.043

29621580

Tsitsimpikou

Chrisostomou

Papalexis

Tsarouhas

Tsatsakis

Jamurtas

The use of nutritional supplements among recreational athletes in Athens, Greece

Int J Sport Nutr Exerc Metab213773842011

10.1123/ijsnem.21.5.377

21799216

Vasilaki

Tsitsimpikou

Tsarouhas

Germanakis

Tzardi

Kavvalakis

Ozcagli

Kouretas

Tsatsakis

Cardiotoxicity in rabbits after long-term nandrolone decanoate administration

Toxicol Lett2411431512016

10.1016/j.toxlet.2015.10.026

26541207

Baggish

Weiner

Kanayama

Hudson

Picard

Hutter

JrPope

Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction

Circ Heart Fail34724762010

10.1161/CIRCHEARTFAILURE.110.958843

20424234

2909423

Tsitsimpikou

Tsarouhas

Spandidos

Tsatsakis

Detection of stanozolol in the urine of athletes at a pg level: The possibility of passive exposure

Biomed Rep56656662016

10.3892/br.2016.794

28105335

5228393

Sattler

Jaque

Schroeder

Olson

Dube

Martinez

Briggs

Horton

Azen

Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus

J Clin Endocrinol Metab84126812761999

10.1210/jcem.84.4.5610

10199766

Santos

Oliveira

Silva

Adverse cardiovascular effects from the use of anabolic-androgenic steroids as ergogenic resources

Subst Use Misuse49113211372014

10.3109/10826084.2014.903751

24832723

Bonetti

Tirelli

Catapano

Dazzi

Dei Cas

Solito

Ceda

Reverberi

Monica

Pipitone

Side effects of anabolic androgenic steroids abuse

Int J Sports Med296796872008

10.1055/s-2007-965808

18004690

Gould

Petty

The male menopause: does it exist? For: Some men need investigation and testosterone treatment

West J Med17376782000

10.1136/ewjm.173.2.76

10924412

1070997

Gillessen

Templeton

Marra

Kuo

Valtorta

Shahinian

Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer

J Natl Cancer Inst102176017702010

10.1093/jnci/djq419

21068432

2994861

Izbicki

Schmitz

Kamran

Izbicki

Androgens as promoters of colon carcinogenesis

Cancer Detect Prev63553621983

6616504

Mehta

Fricks

Moon

Androgen receptors in chemically-induced colon carcinogenesis

Cancer45(Suppl)108510891980

10.1002/1097-0142(19800315)45:5+<1085::AID-CNCR2820451309>3.0.CO;2-M

7357503

Moon

Fricks

Influence of gonadal hormones and age on 1,2-dimethylhydrazine-induced colon carcinogenesis

Cancer40(Suppl)250225081977

10.1002/1097-0142(197711)40:5+<2502::AID-CNCR2820400917>3.0.CO;2-7

922691

Hyde

Flicker

McCaul

Almeida

Hankey

Chubb

Yeap

Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study

Cancer Epidemiol Biomarkers Prev21131913292012

10.1158/1055-9965.EPI-12-0129

22828207

Orsted

Nordestgaard

Bojesen

Plasma testosterone in the general population, cancer prognosis and cancer risk: A prospective cohort study

Ann Oncol257127182014

10.1093/annonc/mdt590

24567517

4433522

Koliarakis

Psaroulaki

Nikolouzakis

Kokkinakis

Sgantzos

Goulielmos

Androutsopoulos

Tsatsakis

Tsiaoussis

Intestinal microbiota and colorectal cancer: a new aspect of research

J BUON23121612342018

30512251

Alberg

Gordon

Hoffman

Comstock

Helzlsouer

Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and the subsequent risk of developing colon cancer

Cancer Epidemiol Biomarkers Prev95175212000

10815698

Anagnostopoulou

Pediaditakis

Alkahtani

Alarifi

Schmidt

Lang

Gravanis

Charalampopoulos

Stournaras

Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: The role of nerve growth factor (NGF) receptors

Endocrinology154244624562013

10.1210/en.2012-2249

23696568

Ferro

Catalano

Raineri

Reato

dell'Eva

Risio

Foà

Fortunati

Pfeffer

Somatic alterations of the androgen receptor CAG repeat in human colon cancer delineate a novel mutation pathway independent of microsatellite instability

Cancer Genet Cytogenet12335402000

10.1016/S0165-4608(00)00296-X

11120331

Slattery

Sweeney

Murtaugh

Wolff

Potter

Caan

Samowitz

Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer

Cancer Epidemiol Biomarkers Prev14293629422005

10.1158/1055-9965.EPI-05-0514

16365013

Hoque

Albanes

Lippman

Spitz

Taylor

Klein

Thompson

Goodman

Stanford

Crowley

Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Cancer Causes Control126276332001

10.1023/A:1011277600059

11552710

Krithivas

Yurgalevitch

Mohr

Wilcox

Batter

Brown

Longcope

McKinlay

Kantoff

Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men

J Endocrinol1621371421999

10.1677/joe.0.1620137

10396030

Ding

Menon

Reddy

Barrack

Effect of a short CAG (glutamine) repeat on human androgen receptor function

Prostate5823322004

10.1002/pros.10316

14673949

Westberg

Baghaei

Rosmond

Hellstrand

Landén

Jansson

Holm

Björntorp

Eriksson

Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women

J Clin Endocrinol Metab86256225682001

10.1210/jc.86.6.2562

11397855

Rudolph

Shi

Försti

Hoffmeister

Sainz

Jansen

Hemminki

Brenner

Chang-Claude

Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: Results from a German population-based case-control study

BMC Cancer148172014

10.1186/1471-2407-14-817

25376484

4232639

Bonin

Bellemain

Bronken Eidesen

Pompanon

Brochmann

Taberlet

How to track and assess genotyping errors in population genetics studies

Mol Ecol13326132732004

10.1111/j.1365-294X.2004.02346.x

15487987

Pompanon

Bonin

Bellemain

Taberlet

Genotyping errors: Causes, consequences and solutions

Nat Rev Genet68478592005

10.1038/nrg1707

16304600

Huang

Wang

Song

Wang

Zhu

Tang

Liu

Chen

Zhang

Muhammad

Polymorphic CAG Repeat and Protein Expression of Androgen Receptor Gene in Colorectal Cancer

Mol Cancer Ther14106610742015

10.1158/1535-7163.MCT-14-0620

25637315

Chamberlain

Driver

Miesfeld

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

Nucleic Acids Res22318131861994

10.1093/nar/22.15.3181

8065934

310294

Choong

Kemppainen

Zhou

Wilson

Reduced androgen receptor gene expression with first exon CAG repeat expansion

Mol Endocrinol10152715351996

10.1210/mend.10.12.8961263

8961263

Ferro

Catalano

Dell'Eva

Fortunati

Pfeffer

The androgen receptor CAG repeat: A modifier of carcinogenesis?

Mol Cell Endocrinol1931091202002

10.1016/S0303-7207(02)00104-1

12161010

Catalano

Pfeffer

Raineri

Ferro

Curto

Capuzzi

Corno

Berta

Fortunati

Altered expression of androgen-receptor isoforms in human colon-cancer tissues

Int J Cancer863253302000

10.1002/(SICI)1097-0215(20000501)86:3<325::AID-IJC4>3.0.CO;2-G

10760818

Papadopoulou

Nasir

Föller

Alevizopoulos

Lang

Stournaras

Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/bad in vitro and in vivo and blocks migration via vinculin/actin signaling

Mol Med1748582011

10.2119/molmed.2010.00120

20957335

Papadopoulou

Gehring

Nasir

Dimas

Bhavsar

Föller

Alevizopoulos

Lang

Stournaras

Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo

Mol Cancer81142009

10.1186/1476-4598-8-114

19948074

2794856

Chesire

Isaacs

Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor

Oncogene21845384692002

10.1038/sj.onc.1206049

12466965

Yoshioka

Nishikawa

Ito

Kawamata

Doi

Yamamoto

Yoshida

Omori

Kotanagi

Masuko

Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin

Cancer Sci101201120182010

10.1111/j.1349-7006.2010.01640.x

20626753

Holgren

Dougherty

Edwin

Cerasi

Taylor

Fichera

Joseph

Bissonnette

Khare

Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: Sprouty/c-Met upregulation in human colonic adenocarcinomas

Oncogene29524152532010

10.1038/onc.2010.264

20661223

2945447

Huynh

Liu

Baldwin

P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways

Biochim Biophys Acta1803110611132010

10.1016/j.bbamcr.2010.05.007

20595063

Teyssier

Khetchoumian

Losson

Stallcup

Transcriptional intermediary factor 1alpha mediates physical interaction and functional synergy between the coactivator-associated arginine methyltransferase 1 and glucocorticoid receptor-interacting protein 1 nuclear receptor coactivators

Mol Endocrinol20127612862006

10.1210/me.2005-0393

16322096

Chen

Hong

Koh

Huang

Schurter

Aswad

Stallcup

Regulation of transcription by a protein methyltransferase

Science284217421771999

10.1126/science.284.5423.2174

10381882

Koh

Lee

Widelitz

Chuong

Stallcup

Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators

J Biol Chem27726031260352002

10.1074/jbc.M110865200

11983685

4386649

El Messaoudi

Fabbrizio

Rodriguez

Chuchana

Fauquier

Cheng

Theillet

Vandel

Bedford

Sardet

Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene

Proc Natl Acad Sci USA10313351133562006

10.1073/pnas.0605692103

16938873

Kim

Lee

Park

Nguyen

Bae

Kwon

Jung

Differential CARM1 expression in prostate and colorectal cancers

BMC Cancer101972010

10.1186/1471-2407-10-197

20462455

2881889

Ilboudo

Fouche

Rizzati

Toé

Gamet-Payrastre

Guissou

In vitro impact of five pesticides alone or in combination on human intestinal cell line Caco-2

Toxicol Rep14744892014

10.1016/j.toxrep.2014.07.008

28962261

5598529

Carroll

Goodlad

Poole

Tyner

Robey

Swanson

Unterman

Reduced susceptibility to azoxymethane-induced aberrant crypt foci formation and colon cancer in growth hormone deficient rats

Growth Horm IGF Res194474562009

10.1016/j.ghir.2009.02.001

19406679

3005240

Chuang

Altuwaijri

Lai

Chu

Lai

Lin

Hsu

Keng

Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor

J Exp Med206118111992009

10.1084/jem.20082521

19414555

2715023

Mårin

Krotkiewski

Björntorp

Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues

Eur J Med13293361992

1341460

Lin

Giovannucci

Sex hormones and colorectal cancer: What have we learned so far?

J Natl Cancer Inst102174617472010

10.1093/jnci/djq444

21068431

2994865

Thevis

Schänzer

Synthetic anabolic agents: Steroids and nonsteroidal selective androgen receptor modulators

Doping in Sports: Biochemical Principles, Effects and Analysis. Handbook of Experimental PharmacologyThieme

Hemmersbach

195

Springer

Berlin, Heidelberg

991262010

10.1007/978-3-540-79088-4_5

Joseph

Parr

Synthetic androgens as designer supplements

Curr Neuropharmacol13891002015

10.2174/1570159X13666141210224756

26074745

4462045

Watanabe

Kobayashi

Exogenous hormones and human cancer

Jpn J Clin Oncol231131993

8459638

Rosner

Khan

Renal cell carcinoma following prolonged testosterone therapy

Arch Intern Med1524264291992

10.1001/archinte.1992.00400140156043

1739383

Martorana

Concetti

Manferrari

Creti

Anabolic steroid abuse and renal cell carcinoma

J Urol162208920891999

10.1016/S0022-5347(05)68110-4

10569579

Bryden

AAG

Rothwell

PJN

O'Reilly

Anabolic steroid abuse and renal-cell carcinoma

Lancet346130613071995

10.1016/S0140-6736(95)91915-5

7475759

Zahm

Fraumeni

The epidemiology of soft tissue sarcoma

Semin Oncol245045141997

9344316

100

Nourbakhsh

Golestani

Zahrai

Modarressi

Malekpour

Karami-Tehrani

Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells

Mol Cell Endocrinol33010162010

10.1016/j.mce.2010.07.021

20673788

101

McKeown-Eyssen

Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk?

Cancer Epidemiol Biomarkers Prev36876951994

7881343

102

Bronson

Matherne

Exposure to anabolic-androgenic steroids shortens life span of male mice

Med Sci Sports Exerc296156191997

10.1097/00005768-199705000-00005

9140897

103

Froehner

Fischer

Leike

Hakenberg

Noack

Wirth

Intratesticular leiomyosarcoma in a young man after high dose doping with oral-turinabol: A case report

Cancer86157115751999

10.1002/(SICI)1097-0142(19991015)86:8<1571::AID-CNCR26>3.0.CO;2-C

10526287

104

Chacon

Monga

Medical management of benign prostatic hyperplasia

Geriatr Nephrol Urol939481999

10.1023/A:1008308819463

10435226

105

Dimitriadis

Mitrou

Lambadiari

Maratou

Raptis

Insulin effects in muscle and adipose tissue

Diabetes Res Clin Pract93(Suppl 1)S52S592011

10.1016/S0168-8227(11)70014-6

21864752

106

Giovannucci

Michaud

The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas

Gastroenterology132220822252007

10.1053/j.gastro.2007.03.050

17498513

107

Yang

Hennessy

Lewis

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients

Gastroenterology127104410502004

10.1053/j.gastro.2004.07.011

15480982

108

Larsson

Orsini

Brismar

Wolk

Diabetes mellitus and risk of bladder cancer: A meta-analysis

Diabetologia49281928232006

10.1007/s00125-006-0468-0

17021919

109

Flood

Mai

Pfeiffer

Kahle

Remaley

Lanza

Schatzkin

Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas

Gastroenterology133142314292007

10.1053/j.gastro.2007.08.040

17904132

110

Polednak

Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: A population-based study

Cancer Detect Prev304664722006

10.1016/j.cdp.2006.07.003

17069990

111

Jullumstrø

Kollind

Lydersen

Edna

Diabetes mellitus and outcomes of colorectal cancer

Acta Oncol483613672009

10.1080/02841860802637765

19101848

112

Schoen

Weissfeld

Kuller

Thaete

Evans

Hayes

Rosen

Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps

Gastroenterology1294644752005

10.1053/j.gastro.2005.05.051

16083703

113

LeRoith

Baserga

Helman

Roberts

Insulin-like growth factors and cancer

Ann Intern Med12254591995

10.7326/0003-4819-122-1-199501010-00009

7619109

114

Sandhu

Dunger

Giovannucci

Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer

J Natl Cancer Inst949729802002

10.1093/jnci/94.13.972

12096082

115

Siddle

Signalling by insulin and IGF receptors: Supporting acts and new players

J Mol Endocrinol47R1R102011

10.1530/JME-11-0022

21498522

116

Mosthaf

Grako

Dull

Coussens

Ullrich

McClain

Functionally distinct insulin receptors generated by tissue-specific alternative splicing

EMBO J9240924131990

10.1002/j.1460-2075.1990.tb07416.x

2369896

552265

117

Abbruzzese

Diodoro

Sperduti

Mileo

Pattaro

De Salvo

Cosimelli

Perrotti

Paggi

Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: Implications for prognosis and clinical outcome

J Cell Physiol2305625672015

10.1002/jcp.24733

25102778

118

Frasca

Pandini

Scalia

Sciacca

Mineo

Costantino

Goldfine

Belfiore

Vigneri

Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells

Mol Cell Biol19327832881999

10.1128/MCB.19.5.3278

10207053

84122

119

Kosaki

Webster

Effect of dexamethasone on the alternative splicing of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells

J Biol Chem26821990219961993

8408055

120

Heckl

Pellinghaus

Krüger

Bosselmann

Wilhelm

Behrens

Schreiber

Röcken

Epithelial insulin receptor expression-prognostic relevance in colorectal cancer

Oncotarget937497375082018

10.18632/oncotarget.26490

30680065

6331016

121

Morcavallo

Genua

Palummo

Kletvikova

Jiracek

Brzozowski

Iozzo

Belfiore

Morrione

Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A

J Biol Chem28711422114362012

10.1074/jbc.M111.252478

22318726

3322853

122

Wang

Häring

Rathjen

Lockhart

Sørensen

Ussar

Rasmussen

Bertagnolli

Kahn

Rask-Madsen

Insulin resistance in vascular endothelial cells promotes intestinal tumour formation

Oncogene36498749962017

10.1038/onc.2017.107

28459466

5578899

123

Laakso

Edelman

Brechtel

Baron

Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM

Diabetes41107610831992

10.2337/diabetes.41.9.1076

1499861

124

Steinberg

Chaker

Leaming

Johnson

Brechtel

Baron

Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance

J Clin Invest97260126101996

10.1172/JCI118709

8647954

507347

125

Rask-Madsen

Ihlemann

Krarup

Christiansen

Kober

Nervil Kistorp

Torp-Pedersen

Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease

Diabetes50261126182001

10.2337/diabetes.50.11.2611

11679442

126

Tabit

Shenouda

Holbrook

Fetterman

Kiani

Frame

Kluge

Held

Dohadwala

Gokce

Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus

Circulation12786952013

10.1161/CIRCULATIONAHA.112.127514

23204109

127

Simpson

Lim

Moritz

Mathivanan

Exosomes: Proteomic insights and diagnostic potential

Expert Rev Proteomics62672832009

10.1586/epr.09.17

19489699

128

Gangoda

Mathivanan

Cortactin enhances exosome secretion without altering cargo

J Cell Biol2141291312016

10.1083/jcb.201606131

27432895

4949455

129

Gangoda

Boukouris

Liem

Kalra

Mathivanan

Extracellular vesicles including exosomes are mediators of signal transduction: Are they protective or pathogenic?

Proteomics152602712015

10.1002/pmic.201400234

25307053

130

Silantyev

Falzone

Libra

Gurina

Kardashova

Nikolouzakis

Nosyrev

Sutton

Mitsias

Tsatsakis

Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics

Cells882019

10.3390/cells8080863

131

Taniguchi

Emanuelli

Kahn

Critical nodes in signalling pathways: Insights into insulin action

Nat Rev Mol Cell Biol785962006

10.1038/nrm1837

16493415

132

Huang

Chen

Obesity, the PI3K/Akt signal pathway and colon cancer

Obes Rev106106162009

10.1111/j.1467-789X.2009.00607.x

19527447

133

Matsuzaki

Daitoku

Hatta

Tanaka

Fukamizu

Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation

Proc Natl Acad Sci USA10011285112902003

10.1073/pnas.1934283100

13679577

134

Liem

Ang

Mathivanan

Insulin Mediated Activation of PI3K/Akt Signalling Pathway Modifies the Proteomic Cargo of Extracellular Vesicles

Proteomics17172017

10.1002/pmic.201600371

135

Baserga

The insulin-like growth factor I receptor: A key to tumor growth?

Cancer Res552492521995

7812953

136

Párrizas

LeRoith

Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product

Endocrinology138135513581997

10.1210/endo.138.3.5103

9048647

137

Wang

Markovich

Lee

Wang

Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells

Endocrinology139135413601998

10.1210/endo.139.3.5801

9492072

138

Remacle-Bonnet

Garrouste

Heller

André

Marvaldi

Pommier

Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways

Cancer Res60200720172000

10766192

139

Liu

Fang

Mendelsohn

Fan

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody

Oncogene20191319222001

10.1038/sj.onc.1204277

11313939

140

Ryan

Goss

The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer

Oncologist1316242008

10.1634/theoncologist.2007-0199

18245009

141

Pollak

The insulin and insulin-like growth factor receptor family in neoplasia: An update

Nat Rev Cancer121591692012

10.1038/nrc3215

22337149

142

Islam

Hooiveld

GJEJ

van den Berg

JHJ

van der Velpen

Murk

Rietjens

IMCM

van Leeuwen

FXR

Soy supplementation: Impact on gene expression in different tissues of ovariectomized rats and evaluation of the rat model to predict (post)menopausal health effect

Toxicol Rep5108710972018

10.1016/j.toxrep.2018.10.012

30425930

6222031

143

Pollak

Giovannucci

Chan

Tao

Hennekens

Stampfer

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3

J Natl Cancer Inst916206251999

10.1093/jnci/91.23.2052

10203281

144

Lahm

Suardet

Laurent

Fischer

Ceyhan

Givel

Odartchenko

Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha

Br J Cancer653413461992

10.1038/bjc.1992.69

1558785

1977598

145

Guo

Narayan

Yallampalli

Singh

Characterization of insulinlike growth factor I receptors in human colon cancer

Gastroenterology102110111081992

10.1016/0016-5085(92)90744-J

1312970

146

Freier

Weiss

Eran

Flyvbjerg

Dahan

Nephesh

Safra

Shiloni

Raz

Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon

Gut447047081999

10.1136/gut.44.5.704

10205209

1727486

147

Hakam

Yeatman

Mora

Marcet

Nicosia

Karl

Coppola

Expression of insulin-like growth factor-1 receptor in human colorectal cancer

Hum Pathol30112811331999

10.1016/S0046-8177(99)90027-8

10534157

148

Lee

Jain

Kim

Lee

Kuller

Princen

In-GuDoKim

Park

Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status

PLoS One9e1035512014

10.1371/journal.pone.0103551

25090459

4121133

149

Soubry

Il'yasova

Sedjo

Wang

Byers

Rosen

Yashin

Ukraintseva

Haffner

D'Agostino

Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps

Int J Cancer1315125172012

10.1002/ijc.26393

21898383

150

Ollberding

Cheng

Wilkens

Henderson

Pollak

Kolonel

Le Marchand

Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: The Multiethnic Cohort study

Cancer Epidemiol Biomarkers Prev218108202012

10.1158/1055-9965.EPI-11-1105

22354904

4494075

151

Giovannucci

Insulin, insulin-like growth factors and colon cancer: A review of the evidence

J Nutr131(Suppl)3109S3120S2001

10.1093/jn/131.11.3109S

11694656

152

Shiratsuchi

Akagi

Kawahara

Kinugasa

Romeo

Yoshida

Ryu

Gotanda

Kage

Shirouzu

Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer

Anticancer Res31254125452011

21873172

153

Peters

Gongoll

Langner

Mengel

Piso

Klempnauer

Rüschoff

Kreipe

von Wasielewski

IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer

Virchows Arch4431391452003

10.1007/s00428-003-0856-5

12845531

154

Furlanetto

Harwell

Frick

Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro

Mol Endocrinol85105171994

10.1210/mend.8.4.8052269

8052269

155

Sahin

Brown

Ordonez

Cleary

el-Naggar

Wilson

Ayala

Assessment of Ki-67-derived tumor proliferative activity in colorectal adenocarcinomas

Mod Pathol717221994

8159647

156

Kubota

Petras

Easley

Bauer

Tubbs

Fazio

Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis

Cancer70260226091992

10.1002/1097-0142(19921201)70:11<2602::AID-CNCR2820701106>3.0.CO;2-W

1423188

157

Cascinu

Del Ferro

Grianti

Ligi

Ghiselli

Foglietti

Saba

Lungarotti

Catalano

Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients

Gastroenterology1137677721997

10.1016/S0016-5085(97)70170-7

9287967

158

Bowers

Rossi

O'Flanagan

deGraffenried

Hursting

The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link

Front Endocrinol (Lausanne)6772015

10.3389/fendo.2015.00077

26029167

4432799

159

Firth

Baxter

Cellular actions of the insulin-like growth factor binding proteins

Endocr Rev238248542002

10.1210/er.2001-0033

12466191

160

Liou

Shun

Liang

Chiu

Chen

Wang

Lin

Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer

J Clin Endocrinol Metab95171717252010

10.1210/jc.2009-2668

20157191

161

Jones

Clemmons

Insulin-like growth factors and their binding proteins: Biological actions

Endocr Rev163341995

10.1210/er.16.1.3

7758431

162

Héron-Milhavet

LeRoith

Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage

J Biol Chem27715600156062002

10.1074/jbc.M111142200

11877395

163

Peretz

Jensen

Baserga

Glazer

ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response

Proc Natl Acad Sci USA98167616812001

10.1073/pnas.98.4.1676

11172010

164

Huang

Khambata-Ford

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer

Clin Cancer Res18115611662012

10.1158/1078-0432.CCR-11-1135

22294722

165

Jones

Goddard

Gee

Hiscox

Rubini

Barrow

Knowlden

Williams

Wakeling

Nicholson

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

Endocr Relat Cancer117938142004

10.1677/erc.1.00799

15613453

166

Albanell

Baselga

Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect

J Natl Cancer Inst93183018322001

10.1093/jnci/93.24.1830

11752000

167

Shen

Cui

Sun

Han

Liu

Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression

J Cell Biochem113208620972012

10.1002/jcb.24080

22275271

168

Warren

Yuan

Matli

Ferrara

Donner

Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma

J Biol Chem27129483294881996

10.1074/jbc.271.46.29483

8910616

169

Akagi

Liu

Zebrowski

Xie

Ellis

Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I

Cancer Res58400840141998

9731515

170

Sekharam

Zhao

Sun

Fang

Zhang

Yuan

Dan

Boulware

Cheng

Coppola

Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway

Cancer Res63770877162003

14633695

171

Zhang

Wang

Song

Knockdown of type I insulin-like growth factor receptor inhibits human colorectal cancer cell growth and downstream PI3K/Akt, WNT/β-catenin signal pathways

Biomed Pharmacother7312182015

10.1016/j.biopha.2015.05.004

26211576

172

Nahor

Abramovitch

Engeland

Werner

The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells

Growth Horm IGF Res153883962005

10.1016/j.ghir.2005.07.005

16181796

173

Ramocki

Wilkins

Magness

Simmons

Scull

Lee

McNaughton

Lund

Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9

Endocrinology1492612672008

10.1210/en.2007-0869

17916629

174

Chan

Lee

Insulin receptor substrates (IRSs) and breast tumorigenesis

J Mammary Gland Biol Neoplasia134154222008

10.1007/s10911-008-9101-9

19030971

2819329

175

Esposito

Aru

Lattanzio

Morgano

Abbondanza

Malekzadeh

Bishehsari

Valanzano

Russo

Piantelli

The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer

PLoS One7e361902012

10.1371/journal.pone.0036190

22558377

3338610

176

Day

Poulogiannis

McCaughan

Mulholland

Arends

Ibrahim

Dear

IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer

Int J Exp Pathol942032112013

23594372

3664965

177

Slattery

Samowitz

Curtin

Hoffman

Caan

Neuhausen

Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer

Cancer Epidemiol Biomarkers Prev13120612142004

15247132

178

Sanchez-Lopez

Flashner-Abramson

Shalapour

Zhong

Taniguchi

Levitzki

Karin

Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling

Oncogene35263426442016

10.1038/onc.2015.326

26364612

179

Krajewski

Dzięgała

Kołodziej

Dembowski

Zdrojowy

Vitamin D and urological cancers

Cent European J Urol691391472016

27551550

4986303

180

Lefkowitz

Garland

Sunlight, vitamin D, and ovarian cancer mortality rates in US women

Int J Epidemiol23113311361994

10.1093/ije/23.6.1133

7721513

181

Uitterlinden

Fang

Van Meurs

Pols

Van Leeuwen

Genetics and biology of vitamin D receptor polymorphisms

Gene3381431562004

10.1016/j.gene.2004.05.014

15315818

182

Boscoe

Schymura

Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002

BMC Cancer62642006

10.1186/1471-2407-6-264

17096841

1665523

183

Bishop

Collins

Okamura

Norman

Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs

J Bone Miner Res9127712881994

10.1002/jbmr.5650090818

7976510

184

Bikle

Vitamin D: Production, Metabolism, and Mechanisms of Action

Endotext [Internet]Feingold

Anawalt

Boyce

MDText.com, Inc.

South Dartmouth, MA

2000

185

Feskanich

Fuchs

Kirkner

Hankinson

Hollis

Giovannucci

Plasma vitamin D metabolites and risk of colorectal cancer in women

Cancer Epidemiol Biomarkers Prev13150215082004

15342452

186

Braun

Helzlsouer

Hollis

Comstock

Colon cancer and serum vitamin D metabolite levels 10–17 years prior to diagnosis

Am J Epidemiol1426086111995

10.1093/oxfordjournals.aje.a117682

7653469

187

Gorham

Garland

Grant

Mohr

Lipkin

Newmark

Giovannucci

Wei

Holick

Vitamin D and prevention of colorectal cancer

J Steroid Biochem Mol Biol971791942005

10.1016/j.jsbmb.2005.06.018

16236494

188

Garland

Shekelle

Barrett-Connor

Criqui

Rossof

Paul

Dietary vitamin D and calcium and risk of colorectal cancer: A 19-year prospective study in men

Lancet13073091985

10.1016/S0140-6736(85)91082-7

2857364

189

Garland

Do sunlight and vitamin D reduce the likelihood of colon cancer?

Int J Epidemiol92272311980

10.1093/ije/9.3.227

7440046

190

Belleli

Shany

Levy

Guberman

Lamprecht

A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis

Carcinogenesis13229322981992

10.1093/carcin/13.12.2293

1335376

191

Comer

Clark

Glauert

Effect of dietary vitamin D3 (cholecalciferol) on colon carcinogenesis induced by 1,2-dimethylhydrazine in male Fischer 344 rats

Nutr Cancer191131241993

10.1080/01635589309514242

8389042

192

Thomas

Tebbutt

Williamson

Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line

Gut33166016631992

10.1136/gut.33.12.1660

1336758

1379578

193

Brehier

Thomasset

Human colon cell line HT-29: Characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone

J Steroid Biochem292652701988

10.1016/0022-4731(88)90275-0

2831436

194

Cross

Farsoudi

Peterlik

Growth inhibition of human colon adenocarcinoma-derived Caco-2 cells by 1,25-dihydroxyvitamin D3 and two synthetic analogs: Relation to in vitro hypercalcemic potential

Naunyn Schmiedebergs Arch Pharmacol3471051101993

10.1007/BF00168780

8446178

195

Vandewalle

Adenis

Hornez

Revillion

Lefebvre

1,25-dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues

Cancer Lett8667731994

10.1016/0304-3835(94)90181-3

7954357

196

Zhao

Feldman

Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells

Endocrinology132180818141993

10.1210/endo.132.4.8384998

8384998

197

Carlberg

Dunlop

An integrated biological approach to nuclear receptor signaling in physiological control and disease

Crit Rev Eukaryot Gene Expr161222006

10.1615/CritRevEukarGeneExpr.v16.i1.10

16584379

198

Padi

Zhang

Rustum

Morrison

Guo

MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice

Gastroenterology1454374462013

10.1053/j.gastro.2013.04.012

23619147

3722307

199

Fernandez-Garcia

Palmer

Garcia

Gonzalez-Martin

del Rio

Barettino

Volpert

Muñoz

Jimenez

1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells

Oncogene24653365442005

10.1038/sj.onc.1208801

16007183

200

Pendás-Franco

Aguilera

Pereira

González-Sancho

Muñoz

Vitamin D and Wnt/β-catenin pathway in colon cancer: Role and regulation of DICKKOPF genes

Anticancer Res 28 (5A)261326232008

201

Ylikomi

Laaksi

Lou

Martikainen

Miettinen

Pennanen

Purmonen

Syvälä

Vienonen

Tuohimaa

Antiproliferative action of vitamin D

Vitam Horm643574062002

10.1016/S0083-6729(02)64010-5

11898396

202

Taghizadeh

Tang

Tai

Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy

Mol Cancer Ther63093172007

10.1158/1535-7163.MCT-06-0517

17237289

203

Pálmer

Sánchez-Carbayo

Ordóñez-Morán

Larriba

Cordón-Cardó

Muñoz

Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells

Cancer Res63779978062003

14633706

204

Jensen

Madsen

Lukas

Binderup

Bartek

Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery

Mol Endocrinol15137013802001

10.1210/mend.15.8.0673

11463860

205

Scaglione-Sewell

Bissonnette

Skarosi

Abraham

Brasitus

A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: Roles of cyclin E, p21Waf1, and p27Kip1

Endocrinology141393139392000

10.1210/endo.141.11.7782

11089522

206

Liu

Chen

Golan

Annunziata

Dougherty

Kong

Musch

Huang

Pekow

Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis

J Clin Invest123398339962013

10.1172/JCI65842

23945234

3754241

207

Murillo

Nagpal

Tiwari

Benya

Mehta

Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer

J Steroid Biochem Mol Biol1214034072010

10.1016/j.jsbmb.2010.03.009

20214986

2905474

208

Kim

Brasitus

The role of vitamin D in normal and pathologic processes in the colon

Curr Opin Gastroenterol1772772001

10.1097/00001574-200101000-00014

17031154

209

Revelli

Massobrio

Tesarik

Nongenomic effects of 1α,25-dihydroxyvitamin D(3)

Trends Endocrinol Metab94194271998

10.1016/S1043-2760(98)00100-3

18406316

210

Norman

Song

Zanello

Bula

Okamura

Rapid and genomic biological responses are mediated by different shapes of the agonist steroid hormone, 1α,25(OH)2vitamin D3

Steroids641201281999

10.1016/S0039-128X(98)00091-9

10323680

211

Sitrin

Bissonnette

Bolt

Wali

Khare

Scaglione-Sewell

Skarosi

Brasitus

Rapid effects of 1,25(OH)2 vitamin D3 on signal transduction systems in colonic cells

Steroids641371421999

10.1016/S0039-128X(98)00102-0

10323682

212

Nelson

Nusse

Convergence of Wnt, beta-catenin, and cadherin pathways

Science303148314872004

10.1126/science.1094291

15001769

3372896

213

Jeanes

Gottardi

Yap

Cadherins and cancer: How does cadherin dysfunction promote tumor progression?

Oncogene27692069292008

10.1038/onc.2008.343

19029934

2745643

214

Rozen

Yang

Huynh

Pollak

Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation

J Natl Cancer Inst896526561997

10.1093/jnci/89.9.652

9150190

215

Kaler

Augenlicht

Klampfer

Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: A crosstalk interrupted by vitamin D3

Oncogene28389239022009

10.1038/onc.2009.247

19701245

2783659

216

Kaler

Galea

Augenlicht

Klampfer

Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells

PLoS One5e117002010

10.1371/journal.pone.0011700

20661477

2908545

217

Chen

Davis

Sitrin

Brasitus

Bissonnette

Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3)

Am J Physiol Gastrointest Liver Physiol283G864G8742002

10.1152/ajpgi.00524.2001

12223346

218

Yanagisawa

Yanagi

Masuhiro

Suzawa

Watanabe

Kashiwagi

Toriyabe

Kawabata

Miyazono

Kato

Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators

Science283131713211999

10.1126/science.283.5406.1317

10037600

219

Deeb

Trump

Johnson

Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics

Nat Rev Cancer76847002007

10.1038/nrc2196

17721433

220

Tong

Hofer

Ellinger

Peterlik

Cross

Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: Relevance for suppression of epidermal growth factor-stimulated cell growth

Oncol Res1177841999

10489163

221

Ben-Shoshan

Amir

Dang

Weisman

Mabjeesh

1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells

Mol Cancer Ther6143314392007

10.1158/1535-7163.MCT-06-0677

17431122

222

Harris

Vitamin D and colon carcinogenesis

J Nutr134(Suppl)3463S3471S2004

10.1093/jn/134.12.3463S

15570055

223

Lappe

Travers-Gustafson

Davies

Recker

Heaney

Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial

Am J Clin Nutr85158615912007

10.1093/ajcn/85.6.1586

17556697

224

Binder

Wittekindt

Ranke

Noonan Syndrome: Genetics and Responsiveness to Growth Hormone Therapy

Horm Res Paediatr6745492007

10.1159/000097552

225

Campbell

Growth-hormone signal transduction

J Pediatr131S42S441997

10.1016/S0022-3476(97)70010-6

9255227

226

Savage

Blum

Ranke

Postel-Vinay

Cotterill

Hall

Chatelain

Preece

Rosenfeld

Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome)

J Clin Endocrinol Metab77146514711993

10.1210/jcem.77.6.7505286

7505286

227

Gunawardane

Hansen

Muller

Christiansen

Jorgensen

JOL

Normal Physiology of Growth Hormone in Adults

Endotext [Internet]Feingold

Anawalt

Boyce

MDText.com, Inc.

South Dartmouth, MA

2000

228

Slater

Murphy

Co-expression of interleukin-6 and human growth hormone in apparently normal prostate biopsies that ultimately progress to prostate cancer using low pH, high temperature antigen retrieval

J Mol Histol3737412006

10.1007/s10735-006-9027-8

16807770

229

Waters

Conway-Campbell

The oncogenic potential of autocrine human growth hormone in breast cancer

Proc Natl Acad Sci USA10114992149932004

10.1073/pnas.0406396101

15479760

230

Brooks

Waters

The growth hormone receptor: Mechanism of activation and clinical implications

Nat Rev Endocrinol65155252010

10.1038/nrendo.2010.123

20664532

231

Brown-Borg

Bartke

GH and IGF1: Roles in energy metabolism of long-living GH mutant mice

J Gerontol A Biol Sci Med Sci676526602012

10.1093/gerona/gls086

22466316

232

Chesnokova

Zonis

Zhou

Recouvreux

Ben-Shlomo

Araki

Barrett

Workman

Wawrowsky

Ljubimov

Growth hormone is permissive for neoplastic colon growth

Proc Natl Acad Sci USA113E3250E32592016

10.1073/pnas.1600561113

27226307

233

Morin

Sparks

Korinek

Barker

Clevers

Vogelstein

Kinzler

Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC

Science275178717901997

10.1126/science.275.5307.1787

9065402

234

Clevers

Nusse

Wnt/β-catenin signaling and disease

Cell149119212052012

10.1016/j.cell.2012.05.012

22682243

235

Koliarakis

Messaritakis

Nikolouzakis

Hamilos

Souglakos

Tsiaoussis

Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer

Int J Mol Sci2041462019

10.3390/ijms20174146

6747549

Figure 1.

Actions of membrane androgen receptors (mARs). mARs have been found to mediate opposing actions to the intracellular androgen receptors. They induce apoptosis through the activation of caspase-3. Furthermore, they phosphorylate vinculin in cancer cells, leading to the inhibition of their migration. The suppression of β-catenin transcription leads to decreased expression of β-catenin target oncogenes, including cyclin D1. Finally, the long-term activation of mAR has been linked to the dephosphorylation of PI3K. As a result, Akt is downregulated and the motility of the colon cancer cells and their invasiveness are reduced. IGF-R, insulin-like growth factor receptor; IRS-1, insulin receptor substrate 1; IGFBPs, insulin-like growth factor binding proteins; ERK, extracellular signal-regulated kinase; VEGF, vascular endothelial growth factor.

Figure 2.

Mechanisms mediated through IGF-1/IGF-1R. The activation of IGF-1R takes place following the bondage of IGF-1 (or IGF-2) to the extracellular part of the receptor. IGF-1 plasma levels, and thus IGF-1R activation, are reduced by the IGFBPs. However, IGFBP-3 can act as an enhancer of the IGF-1 activity when it is bonded to the receptor and not directly to IGF-1. Following its activation, IGF-1R induces the phosphorylation of IRS-1,2 molecules, which they further activate the PI3K-Akt pathway. Consequently, there is induction of cell survival, cell cycle progression, cell proliferation and VEGF transcription. At the same time, apoptosis is inhibited and the cell gains resistance against cancer therapies. Even when IRS-1,2 molecules are silenced, the activation of IGF-1R leads to increased cell proliferation through the activation of Shc-ERK pathway. IRS-1, insulin receptor substrate 1; IGFBPs, insulin-like growth factor binding proteins; ERK, extracellular signal-regulated kinase; VEGF, vascular endothelial growth factor.

Figure 3.

Mechanisms mediated through vitamin D. The insertion of vitamin D into a colorectal cell triggers multiple pathways; both in the cytoplasm (non-genomic actions of vitamin D) and in the nucleus (genomic actions of vitamin D). Through its non-genomic actions, vitamin D halts tumor development through he inhibition of VEGF, EGF, Ras-signaling and TGF-β. At the same it induces IGFBP-5 production, diminishing this way the cancer-promoting effects of IGF-1,2. Also of importance is the reprogram of TAMs, which results in lower levels of IL-1 production. Consequently, the Wnt-pathway is halted, while apoptosis through the TRAIL pathway is triggered. Followin bondage with the VDR it can either bind β-catenin (inhibiting its translocation to the nucleus) or, after being heterodimerized with the RXR, translocates to the nucleus. In the nucleus, the complex vitamin D-VDR-RXR binds to VDREs gene sequences. As an aftermath, the induction of the anti-angiogenic factor thrombospondin 1 occurs, as well as apoptosis through the SPARC pathway and transcription of Wnt-inhibitors. Finally, the inhibition of NF-κB and TLR-2,4, while tumor growth is halted (through inhibition of CDK-Is, cyclin D1, c-myc, etc). ERK, extracellular signal-regulated kinase; VEGF, vascular endothelial growth factor; TAMs, tumor-associated macrophages; VDR, vitamin D receptor; RXR, retinoid X receptor; VDREs, vitamin D response elements; SPARC, secreted protein acidic and rich in cysteine.

Table I.

Association between anabolic hormones and CRC.

Substance	Relation to CRC	Author (year)/(Refs.)	Nature of the study
Testosterone	Physiological testosterone levels induce reduction in tumor incidence especially in right colon	Izbicki et al (1986) (22)	In vivo
	Hypotestosteronemia contributes to CRC	Gould and Petty (53)	In vivo
	development	Gillesen et al (54)	Epidemiological
	Androgens may act as promoters of CRC	Amos-Landgraf et al (2)	In vivo
		Izbicki et al (1983) (55)
		Mehta et al (56)
		Moon and Fricks (57)
	Androgens may play an active role in the adenoma => carcinoma sequence	Fearon and Vogelstein (6)	In vivo
	Increased testosterone levels have no connection	Hyde et al (58)	Epidemiological
	with CRC	Orsted et al (59)
Dehydroepiandrosterone	DHEA levels are inversely associated with	Alberg et al (61)	Epidemiological
(DHEA)	CRC risk	Anagnostopoulou et al (62)	In vitro
Androgen receptors	Number of CAG repeats is linearly correlated	Slattery et al (2005) (64)	Epidemiological
(ARs)	with CRC in men and inversely in women	Westberg et al (68)
	Number of CAG repeats is independent from	Rudolph et al (69)	Epidemiological
	CRC survival rate
	Long CAG repeats	Huang et al (72)	Epidemiological
	Increased risk for CRC in both sexes
	Poor 5-year survival
	High T and N stage
	Few CAG repeats protect against CRC
	mARs seem to mediate opposite actions than iARs	Gu et al (2011) (77)	In vitro
Synthetic	AASs positive correlation with a variety of	Watanabe and	Epidemiological
anabolic agents	cancers (among which is adenocarcinoma)	Kobayashi (95)
(AAS and SARMs)	SARMs are linked with prostate cancer but not	Rosner and Khan (96)
	with CRC	Martorana et al (97)
		Bryden et al (98)
		Zahm and Fraumeni (99)
		Bronson and Matherne (102)	In vivo
		Froehner et al (103)
		Chacon and Monga (104)
Insulin	Long-term insulin therapy/ high blood insulin	Yang et al (107)	Epidemiological
	levels	Larsson et al (108)
	Increased risk of CRC	Flood et al (109)
	Greater risk of CRC recurrence
	No connection between diabetes and CRC-specific	Polednak (110)	Epidemiological
	death	Jullumstrø et al (111)
Epithelial insulin	EIR expression results to distant metastasis,	Heckl et al (120)	Epidemiological
receptor (EIR)	lymphatic invasion, lymph node metastasis, tumor	Morcavallo et al (121)	In vitro
	specific survival and overall survival
Vascular insulin receptor	VIR is frequently found in CRC, especially	Heckl et al (120)	Epidemiological
(VIR)	in left-sided CRCs, and associated with tumor
	invasiveness
Insulin-like growth	High levels of IGF-1 are related with CRC	Soubry et al (149)	In vivo
factor 1 (IGF-1)		Lee et al (148)	In vitro
		Ma et al (143)	Epidemiological
		Ollberding et al (150)
		Giovannucci (2001) (151)
		Shiratsuchi et al (152)
	IGF-1 expression is associated with tumor	Shiratsuchi et al (152)	Epidemiological
	size and depth of invasion
IGFBPs	High IGFBP2 positively associated with reduced	Liou et al (160)	Epidemiological
	overall survival in CRC
Vitamin D	Low levels of vitamin D can induce the	Boscoe and Schymura	Epidemiological
	progression of CRC	(182)
	Levels of 25-OH-vitamin D >20ng/ml can protect	Braun et al (186)	Epidemiological
	against CRC	Gorham et al (187)
	Levels of 25-OH-vitamin D >82ng/ml cancer incidence is decreased by 50%
	Vitamin D can induce the promoter of onco-protective miR-627	Padi et al (198)	In vivo
	Vitamin D in human colon tumor cells up-regulates the potent anti-angiogenic factor thrombospondin 1	Fernandez-Garcia et al (199)	In vitro
	Vitamin D up-regulates the transcription of the Wnt-inhibitors DICKKOPF-1 and	Pendás-Franco et al (200)	In vitro
	DICKKOPF-4
	Vitamin D regulates apoptosis through SPARC	Ylikomi et al (201)	In vitro
		Taghizadeh et al (202)
	Vitamin D down-regulates NF-κB, TLR2 and	Liu et al (206)	In vitro
	TLR4	Kim and Brasitus (2001) (208)
	Vitamin D may be able to reprogram the tumor-associated macrophages (TAM) and halt their tumor-promoting actions	Kaler et al (215)	In vitro
Growth hormone (GH)	Growth hormone suppresses p53, PTEN, and APC	Brown-Borg et al (231)	Epidemiological
		Chesnokova et al (232)	In vivo
		Morin et al (233)	In vivo
		Clevers and Nusse (234)

CRC, colorectal cancer; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; SPARC, secreted protein acidic and rich in cysteine; TLR, Toll-like receptor; PTEN, phosphatase and tensin homolog; APC, adenomatous polyposis coli.